Table 1.
Patient and disease characteristics
| Variable | |
|---|---|
| Age (years), median (range) | 62 (32–76) |
| BMI (kg/m2), median (range) | 23.1(20.7–26.7) |
| Stage, n (%) | |
| FIGO IIIC | 9 (64.3) |
| FIGO IV | 5 (35.7) |
| Histology, n (%) | |
| Serous | 13 (92.9) |
| Clear cell | 1 (7.1) |
| ASA class, n (%) | |
| I-II | 10 (71.4) |
| III | 4 (28.6) |
| Comorbidity, n (%) | 5 (35.7) |
| CA125 (median, range) | |
| Pre-NLHIPEC | 1014 (194–6536) |
| After NLHIPEC | 298 (48–1947) |
| After the 3rd NACT | 42 (10–344) |
| After IDS | 20 (7–81) |
| Percent decrease (CA125 Pre-NLHIPEC － CA125 after the 3rd NACT/CA125 Pre-NLHIPEC) (%), median (range) | 94.7 (86.3–99.4) |
| Patients with CA125<35 U/mL following the the 3rd NACT, n (%) | 6 (42.9) |
| Patients with ascites at diagnosis, n (%) | 9 (64.3) |
| Fagotti score assessed by laparoscopy | |
| 8 | 9 (64.3) |
| 10 | 3 (21.4) |
| 12 | 2 (14.3) |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy; NLHIPEC, neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy.